YOUR STUDY LIBRARY
Topic index ↗
DETAILED NOTE / 01.09

Pharmacology principles

BDS coreBiomedical foundations

Pharmacokinetics describes drug exposure over time; pharmacodynamics describes effects at the target. Apply both to the patient, indication and medicine rather than assuming that a usual dose produces a usual response in everyone.

5 min study read·Practise recall
START WITH THE ESSENTIALS

Quick revision summary

Absorption, routes and bioavailability

Absorption moves a drug from its administration site into the circulation. Route, formulation, local blood flow, gastrointestinal conditions and interactions can change both its speed and extent. Intravenous administration delivers the dose directly to systemic circulation; swallowed medicines may be incompletely absorbed and undergo metabolism before reaching it.

Dosing intervals, loading and steady state

A loading dose aims to establish a target concentration promptly and is linked to distribution and bioavailability. Maintenance dosing replaces what is eliminated and is linked to clearance, interval and bioavailability.

Turn the principles into a prescription decision

Confirm the diagnosis and indication first, then assess contraindications, allergy details, pregnancy where relevant, organ function, current medicines and practical ability to use the formulation. Check the medicine-specific dose, duration and interactions in current references.

Common mistake

Potency is not efficacy, and apparent recovery is not proof that a drug has been eliminated. Reduced clearance and increased pharmacodynamic sensitivity are different reasons for an exaggerated response.

DETAILED TEACHING

Pharmacology principles

Pharmacokinetics describes drug exposure over time; pharmacodynamics describes effects at the target. Apply both to the patient, indication and medicine rather than assuming that a usual dose produces a usual response in everyone.

Absorption, routes and bioavailability

Absorption moves a drug from its administration site into the circulation. Route, formulation, local blood flow, gastrointestinal conditions and interactions can change both its speed and extent. Intravenous administration delivers the dose directly to systemic circulation; swallowed medicines may be incompletely absorbed and undergo metabolism before reaching it.

Bioavailability is the fraction reaching systemic circulation unchanged. First-pass metabolism in gut and liver can reduce that fraction. A dose administered by one route therefore cannot automatically be substituted milligram for milligram by another. Modified-release, buccal, topical and injectable formulations are designed for different delivery characteristics and should not be treated as interchangeable labels.

Distribution, protein binding and effect-site delay

Distribution depends on perfusion, membrane permeability, tissue binding and the unbound fraction in plasma. Volume of distribution is an apparent volume relating the amount in the body to the measured plasma concentration; it is not a literal fluid compartment. A large value can reflect extensive tissue distribution.

Protein binding creates bound and unbound fractions; free drug is available to distribute and interact with targets. Changes in albumin, tissue composition or other medicines may alter exposure, but the clinical consequence depends on the full kinetic system. Plasma concentration and target effect can also be separated by a delay, so rapid repeated dosing before the peak effect is apparent can overshoot the intended response.

Metabolism, elimination and half-life

Metabolism transforms medicines into products that may be inactive, active or toxic. Hepatic enzymes, including cytochrome P450 pathways, are important for many drugs, but metabolism occurs in other tissues too. Renal excretion removes some unchanged medicines and many metabolites. Impairment can therefore affect the parent drug, its metabolites or both.

Clearance is the volume of plasma effectively cleared of drug per unit time. In a simple linear model, elimination half-life depends on clearance and volume of distribution. Reduced clearance can prolong exposure and increase accumulation with repeated dosing. Renal dosing advice may require a specified measure of renal function; use the parameter and method stated for that medicine rather than assuming every reported kidney value is interchangeable.

Dosing intervals, loading and steady state

A loading dose aims to establish a target concentration promptly and is linked to distribution and bioavailability. Maintenance dosing replaces what is eliminated and is linked to clearance, interval and bioavailability. A change in clearance does not automatically require the same proportional change to both loading and maintenance dosing.

With first-order linear kinetics and a stable regimen, repeated dosing approaches steady state over several half-lives. Four half-lives represent about 94% and five about 97% of the eventual approach. The same model helps explain washout. Saturable elimination, active metabolites, changing organ function or altered dosing can make this simple rule unreliable.

ParameterMeaningQuestion it helps answer
BioavailabilityFraction reaching systemic circulation unchangedCan routes or formulations be compared?
Volume of distributionAmount–plasma concentration relationshipHow much drug reaches the desired initial concentration?
ClearanceEffective removal volume per unit timeWhat maintenance exposure will repeated dosing produce?
Half-lifeTime for concentration to halve in a stated modelHow long until accumulation or washout approaches completion?

Targets, dose–response and therapeutic range

An agonist activates a target; an antagonist blocks a response without producing the same activation. Affinity describes binding, while efficacy describes ability to produce a response. Potency concerns the dose or concentration needed for a specified effect. A more potent medicine is not automatically more effective at its maximum or more suitable for the patient.

Therapeutic benefit and harm can overlap. A narrow therapeutic range makes changes in exposure especially important. Pharmacodynamic sensitivity can change even without altered concentration, for example when frailty or concurrent sedatives increase vulnerability to a given effect. Titration requires an appropriate setting, timing and monitoring; it does not make unlimited increments safe.

Interactions and adverse reactions

Pharmacokinetic interactions change absorption, distribution, metabolism or elimination. Pharmacodynamic interactions change the combined effect, such as additive sedation or bleeding. Some combinations involve both. Enzyme inhibition and induction have different mechanisms and time courses, so use an interaction reference for the actual pair rather than assuming all medicines in a broad category behave identically.

Record all prescribed, non-prescribed, herbal and recreational substances. In dental practice, combinations involving anticoagulants, azole antifungals, macrolides, metronidazole, NSAIDs and sedatives may be relevant. An adverse reaction is not always allergy: specify the symptoms, timing and severity. Serious delayed reactions matter as well as immediate ones. Suspected reportable reactions can be submitted through MHRA Yellow Card without proving causality.

Turn the principles into a prescription decision

Confirm the diagnosis and indication first, then assess contraindications, allergy details, pregnancy where relevant, organ function, current medicines and practical ability to use the formulation. Check the medicine-specific dose, duration and interactions in current references. A pharmacology formula explains a parameter; it is not independent authority to improvise a clinical regimen.

Give clear instructions on use, relevant adverse effects and when review is needed. Record why a medicine is necessary and plan to assess benefit and harm. If treatment fails, reconsider diagnosis, source control, adherence and exposure before increasing the dose or adding another medicine. The prescription is one component of treatment rather than a substitute for the underlying intervention.

A distinction to remember

Potency is not efficacy, and apparent recovery is not proof that a drug has been eliminated. Reduced clearance and increased pharmacodynamic sensitivity are different reasons for an exaggerated response.

APPLY IT TO A CASE

A sedative is given in small increments, but the patient becomes much more sedated several minutes later. How can small doses cause a large final effect?

Reveal the reasoning

Earlier increments may not have reached their full effect when additional doses were given. Effect-site delay and accumulation combine, and sensitivity varies between patients. Appropriate titration includes sufficient time, monitoring and the correct clinical setting rather than relying on each increment being small.

Test your recall

What is bioavailability?

Show answer
MODEL ANSWER

It is the fraction of an administered dose that reaches systemic circulation unchanged. Absorption and first-pass metabolism can reduce it after oral administration. It differs from how strongly a drug binds its target or the maximum effect the drug can produce.

More questions on this topic

All Biomedical foundations topics

Find your next topic

Search topics, diagrams, schools and revision guides.

Reference image